Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Financial Statements
Historical financial data — 5 statements covering FY2021–FY2024
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscie...
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s revenue increased 7.5% year over year, from $4.26T to $4.58T.
Net income decreased 25.0% over the same period, from $144.20B to $108.14B.
Over the 3-year period from FY2021 to FY2024, revenue grew by 28% in total.
Total debt decreased by 6.8% to $4.52T.
The debt-to-equity ratio stands at 0.65, indicating a moderate leverage profile.
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) maintains a moderate net profit margin of 2.4%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2021 | $3.57T | $230.06B | $2.46T | $460.84B | N/A | $13.18T | $4.35T | $5.68T |
| FY2022 | $4.03T+12.8% | $317.02B | $2.78T | $490.50B | N/A | $13.96T | $4.38T | $6.35T |
| FY2023 | $4.26T+5.9% | $144.20B | $2.84T | $214.07B | N/A | $15.11T | $4.84T | $7.27T |
| FY2024 | $4.58T+7.5% | $108.14B | $3.00T | $342.59B | N/A | $14.25T | $4.52T | $6.94T |